Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

New Fish-oil drug will hit the market courtesy of AstraZeneca

 (Image source: nutraceuticalsworld.com)

AstraZeneca plc (LON:AZN) received FDA approval for its drug Epanova, a heart disease treatment pill. The drug is derived from fish oil and came from its acquisition of Omthera Pharmaceuticals. Analysts are projecting annual sales for the drug at $322 million. The fish-oil heart pill will be entering a crowded field, but introducing a new drug to the market will give AstraZeneca added strength to fend off  the takeover pursuit from Pfizer Inc. (NYSE:PFE). As a way to fight Pfizer’s pursuit, AstraZeneca also outlined a long-term plan that would generate annual sales of $45 billion by 2023.